导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.57% | 2253/4766 |
| 近一周 | -1.40% | 2121/5456 |
| 近一月 | -1.95% | 1393/5412 |
| 近一季 | -3.81% | 1689/5222 |
| 近半年 | -1.06% | 1661/4911 |
| 近一年 | 4.43% | 1854/4391 |
| 近两年 | 41.74% | 1825/2953 |
| 近三年 | 29.01% | 1119/2252 |
| 成立以来 | 16.61% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.11% 3043/4961 |
8.85% 2528/5312 |
- - |
- - |
| 2025 | 16.17% 2478/4813 |
0.10% 1977/3635 |
2.02% 1942/4076 |
11.58% 3149/4524 |
1.96% 1133/4813 |
| 2024 | 16.44% 811/3463 |
1.91% 845/2808 |
0.50% 592/3014 |
14.83% 1898/3129 |
-1.00% 1562/3463 |
| 2023 | -4.54% 683/2656 |
4.67% 889/2280 |
-3.05% 735/2385 |
-1.24% 497/2515 |
-4.75% 1160/2655 |
| 2022 | -16.99% 540/2207 |
-11.64% 536/1919 |
7.37% 490/2016 |
-13.32% 881/2113 |
0.96% 1418/2208 |
| 2021 | -2.31% 846/1822 |
-0.55% 373/1255 |
4.54% 875/1330 |
-6.93% 1006/1466 |
0.96% 1034/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富沪深300指数增强C VS. 长安沪深300非周期A(740101) |